NEW YORK (GenomeWeb News) – Molecular diagnostics firm XDx is restructuring its business, which will include cutting 25 jobs, the Brisbane, Calif.-based firm said today.
 
XDx said that it is shifting its priorities to efforts that will increase research, development, and commercial activities in support of its AlloMap test for management of heart transplant patients. The firm intends to continue “selected activities” in autoimmunity.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.